ライブラリ登録: Guest
Begell Digital Portal Begellデジタルライブラリー 電子書籍 ジャーナル 参考文献と会報 リサーチ集
Critical Reviews™ in Immunology
インパクトファクター: 1.352 5年インパクトファクター: 3.347 SJR: 0.657 SNIP: 0.55 CiteScore™: 2.19

ISSN 印刷: 1040-8401
ISSN オンライン: 2162-6472

巻:
巻 39, 2019 巻 38, 2018 巻 37, 2017 巻 36, 2016 巻 35, 2015 巻 34, 2014 巻 33, 2013 巻 32, 2012 巻 31, 2011 巻 30, 2010 巻 29, 2009 巻 28, 2008 巻 27, 2007 巻 26, 2006 巻 25, 2005 巻 24, 2004 巻 23, 2003 巻 22, 2002 巻 21, 2001 巻 20, 2000 巻 19, 1999 巻 18, 1998 巻 17, 1997 巻 16, 1996 巻 15, 1995 巻 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v29.i3.50
pages 255-273

Traditional Concepts and Future Avenues of Glucocorticoid Action in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis Therapy

Fred Luhder
Institute for Multiple Sclerosis Research, University of Göttingen and Gemeinnützige Hertie-Stiftung, Waldweg 33, 37073 Göttingen, Germany
Holger Reichardt
Institute of Cellular and Molecular Immunology, University of Goettingen Medical School

要約

Glucocorticoids (GCs) constitute one of the oldest families of anti-inflammatory and immunosuppressive drugs. Since their first clinical use more than half a century ago, they have been employed for therapeutic invention in a variety of conditions, including atopic disorders, autoimmune diseases, and cancer. Nevertheless, their exact mechanism of action is still incompletely understood. In this review, we elaborate especially on the mechanism of GCs in experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis (MS), and summarize our current knowledge on how therapeutic and endogenous GCs impact the pathogenesis of EAE and MS. This includes findings obtained from genetically modified mice and rats lacking or overexpressing the GC receptor (GR) in specific cell types, and the analysis of new pharmaceutical formulations and chemical GC modifications aimed at improving treatment efficacy and specificity. Stimulated by these recent developments, it can be anticipated that novel therapeutic regimens will find their way into clinical practice for the benefit of affected patients.


Articles with similar content:

Diverse Signaling Pathways and Current Status of Molecular Targeted Treatments for Hepatocellular Carcinoma
Critical Reviews™ in Eukaryotic Gene Expression, Vol.27, 2017, issue 4
Ali Sharif, Wafa Majeed, Bushra Akhtar, Muhammad Furqan Akhtar, Faqir Muhammad
Drug Combinations with HDAC Inhibitors in Antitumor Therapy
Critical Reviews™ in Oncogenesis, Vol.20, 2015, issue 1-2
Noemi Arrighetti, Cristina Corno, Laura Gatti
Modulation of Immune Responses by Histone Deacetylase Inhibitors
Critical Reviews™ in Oncogenesis, Vol.20, 2015, issue 1-2
Heiko Brennenstuhl, Ulrike Naumann, Sonja Schotterl
Microencapsulation: An Acclaimed Novel Drug-Delivery System for NSAIDs in Arthritis
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.27, 2010, issue 6
T. M. Pramod Kumar, B. Shivakumar, K. M. Manjanna
Nanotechnology: An Emerging Therapeutic Option for Breast Cancer
Critical Reviews™ in Eukaryotic Gene Expression, Vol.28, 2018, issue 2
Sehrish Murtaza, Zulfia Hussain, Junaid Ali Khan